ARTIVeda™ is positioned to address the COVID-19 pandemic in India.

Deployed broadly, ARTIVeda has the ability to stop the pandemic in India by cutting R0 by at least 50 percent.

Oncotelic will launch an Ayurvedic therapeutic for COVID-19, with its India partner Windlas Biotech Private Ltd. (Windlas), in late-December 2020. The product, ARTIVeda, is a formulated plant extract of the indigenous plant Artemisia, known in Sanskrit texts as Damanaka and Indhana.  ARTIVeda is the first Ayurvedic drug against COVID-19 through TGF-β inhibition. ARTIVeda is expected to be effective through the entire infection cycle.

Oncotelic ARTIVeda

ARTIVeda can be limited for use in only people who are potentially or confirmed infected with COVID-19 (i.e., 10 percent of total population) further reducing the cost to a fraction of allopathic drugs such as Remdesivir.

Mechanism of Action

As a TGF-β inhibitor ArtiVeda targets Covid-19 by suppressing both viral replication and clinical symptoms that arise from viral infection. With treatment, viral replication is suppressed, IFNβ is induced and innate and adaptive immune responses are suppressed.  The end result is protection from both viral and immune driven pathologies (ARDS and cytokine storm).


The active component of ARTIVeda™ has been identified as artemisinin. Through proprietary GMP quality extraction and manufacturing processes, the Artemisia extract was rendered active against SARS-CoV-2.  Testing performed at the US NIAID Core Viral Laboratory discovered that Artemisinin is highly potent at inhibiting the ability of the COVID-19 causing virus (SARS-CoV-2) to multiply while also having an excellent safety index. Our results indicate that Artemisinin has an EC50 of 0.45 ug/ml and Safety Index of 140.

Clinical Study (ARTI-19)

Oncotelic and Windlas have initiated a global clinical trial scaling to 300 patients at 6 sites in India (including the prestigious AIIMS) with CTRI registration number: CTRI/2020/09/028044. ARTI-19 is a prospective, randomized, controlled, open label clinical trial targeting mild and moderate patients (WHO scale 2,3,4 and 5). Scaling to 3,000 patients worldwide, the company has opened study arms in Nigeria and is planning to open sites in Latin America.  The World Health Organization and Oncotelic are exploring ways to expand the study worldwide.

A similar product, ArtiShield, will be marketed outside of India.

Copyright © 2020 Oncotelic Inc., a TGF ImmunoOncology Company. All rights reserved.